Lane Weaver

• BD @ Genentech, but opinions are own • Passed marshmallow test...recently • Achilles heel = Data-driven arguments

[Lane Weaver @laneweaverz]

Drew's recipe for success:
1) Find: tennis ball
2) Select: circle
3) Remember: 30k

#aspirational #✔

http://t.co/K2NBD3bXXT

[Lane Weaver @laneweaverz]

@Atelfo Congrats Alex — would love to give the product a test drive at some point!

[Lane Weaver @laneweaverz]

@srikosuri -- you're right on all accounts in these threads (re:Eroom's Law et al) -- and it's extremely frustrating and tragic that more well-meaning people (e.g., Ezra) don't dig deeper to truly get to the kernel the issue.

I'll send you some data that provides further context. Also Peter has been beating this drum for years.

[Lane Weaver @laneweaverz]

@KevinBenSmith @KevinBenSmith Great work w/the app and its evolution (I’m an early convert).

In terms of sharing — screenshot is nice, but it would be 🔥if I could share a playlist built from a tag. So a friend could learn from all the eg #productivity snips I’ve collected from diff places

[Lane Weaver @laneweaverz]

@joannezchen The good folks over at @TheHustle anticipated your problem.

And based on their Pitchbook, Flappie could use some funding …

[Lane Weaver @laneweaverz]

@srikosuri Yeah, those are all the things I've been doing as well.
For #1, though, from spot checking some positive controls, I still have too much doubt to use "out-of-the-box" to learn about an unknown domain without verifying via traditional keyword search.

[Lane Weaver @laneweaverz]

@srikosuri @srikosuri -- I'm curious -- what good use cases do you use LLMs for in life / work?

I've been test driving in the legal / contracting domain, but it's not ripe yet

[Lane Weaver @laneweaverz]

@dagarfield @srikosuri The labor component of cost has been increasing. Baumol (who Sri cites) suggested that the mechanism is due to labor market competition, in which Educ & HC need to offer competitive wages vs other sectors that are more productive and thus can pay higher salaries (e.g., Tech)

[No Patient Left Behind @NPLB_org]

“Many patient advocacy groups have had the same experience. @icer_review takes our time and effort, our patients’ time and effort, yet it is consistently clear that they already know what their outcome will be.” Read about ICER's faulty methods/math here:
https://t.co/AaERgfhAf0

[Lane Weaver @laneweaverz]

@srikosuri Thanks for posting — I had to educate an industry friend (who should know better) on this subject recently. And price is just 1 dimen. in a conver. that should include value, resource alloc., & budgetary time horizons — topics that matter in long term, but r seldom discussed

[Drug Channels @DrugChannels]

Good reminder to be humble: @USCBO overestimated #healthcare spending by $1.1 TRILLION from 2010 to 2020

"Less-than-anticipated spending for prescription #drugs in #Medicare Part D" was big source of error

#oops ¯\_(ツ)_/¯

https://t.co/6b87DwRQjw

[Lane Weaver @laneweaverz]

@natashaloder @PeterKolchinsky @ZacharyBrennan Unfortunately we can't do a counterfactual history -- but going forward, the answer is fairly apparent -- if you subtract the U.S. market from the returns in the third panel from your publication, we will have less new products than we otherwise would have

[Novome Biotechnologies @novomebio]

#News: Excited to share we’ve secured $43.5 million in our Series B financing to advance our ongoing Phase 2a clinical trial in #hyperoxaluria and pipeline of #GEMMs candidates for #IBD. Learn more: https://t.co/DrY9hgxLGu #celltherapy #livingmedicines

[Lane Weaver @laneweaverz]

The NIH, R&D, and the first mile of the marathon - a conversation with John LaMattina — RApport https://t.co/fTt8WPSOh7

[Lane Weaver @laneweaverz]

@SenFeinstein IRA is a step forward for Climate and OOP costs, but a step backward for new therapies & future patients.

It's hard to innovate when you're NPV negative, as The Economist points out

https://t.co/YU82gggmKY

[Lane Weaver @laneweaverz]

@JakeAuch IRA is a step forward for Climate and OOP costs, but a step backward for new therapies & future patients.

It's hard to innovate when you're NPV negative, as The Economist points out

https://t.co/YU82gggmKY

[Lane Weaver @laneweaverz]

@PeterKolchinsky @peterbachmd @roncohenshair @EricTopol @SherylNYT @RebeccaDRobbins We’re unnecessary handicapping ourselves -- it’s somehow cosmically sad that we’re lobbing grenades at each other, rather than standing shoulder-to-shoulder tackling disease together

[Lane Weaver @laneweaverz]

@PeterKolchinsky @peterbachmd @roncohenshair @EricTopol @SherylNYT @RebeccaDRobbins Drug dev. is a wickedly hard problem where we need all hands on deck (sector is NPV neg., and it’s not for a lack of smart people or good decision-making).
https://t.co/wkkHXgCUkF